Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2025-12-24 @ 10:58 PM
NCT ID:
NCT00585169
Eligibility Criteria:
Inclusion Criteria:
* Clinical diagnosis of Pathological Gambling using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (Grant et al., 2004);
* Gambling behavior within 2 weeks prior to enrollment;
* For women, negative results on a urine pregnancy test and stable use of a medically accepted form of contraception.
Exclusion Criteria:
* Infrequent gambling (i.e. less than one time per week) that does not meet DSM-IV criteria for PG;
* Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen;
* History of seizures;
* Myocardial infarction within 6 months;
* Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
* A need for medication other than memantine with possible psychotropic effects or unfavorable interactions;
* Clinically significant suicidality;
* Current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders (Grant et al., 2005), except for nicotine dependence;
* Lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID;
* Current or recent (past 3 months) DSM-IV substance abuse or dependence;
* Positive urine drug screen at screening;
* Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;
* Previous treatment with memantine;
* Treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Maximum Age:
75 Years
Study:
NCT00585169
Study Brief:
Protocol Section:
NCT00585169